Rothenfußer Lab

Doctoral students as co-authors are underlined (starting in 1998)

• Santos-Peral, A., F. Luppa, S. Goresch, E. Nikolova, M. Zaucha, L. Lehmann, F. Dahlstroem, H. Karimzadeh, J. Thorn-Seshold, E. Winheim, E.-M. Schuster, G. Dobler, M. Hoelscher, B.M. Kümmerer, S. Endres, K. Schober, A.B. Krug, M. Pritsch, G. Barba-Spaeth, and S. Rothenfusser.
Prior flavivirus immunity skews the yellow fever vaccine response to expand cross-reactive antibodies with increased risk of antibody dependent enhancement of Zika and dengue virus infection.
  Nature communications, 2024 (in press).
  JIF2022 17.7
  Prepublished on Bioarchives: https://doi.org/10.1101/2023.05.07.539594
• Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou A, Schuebel M, Jobst J, Zhang T, Doerr J, Mearkl F, Majed L, Meuller PJ, May P, Gottschlich A, Tokarew N, Leucke J, Oener A, Schwerdtfeger M, Andreu-Sanz D, Gruenmeier R, Seifert M, Michaelides S, Hristov M, Koenig LM, Cadilha B, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell R, Cerezo-Wallis D, Tejedo C, Soengas M, Bald T, Huber S, Endres S, Kobold S.
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.

  Immunity 2023; 143-161.e11.

  JIF2022 43.5

  https://authors.elsevier.com/sd/article/S107476132200646X
  
• Winheim E, Eser T, Deák F, Ahmed MIM, Baranov O, Rinke L, Eisenächer K, Santos-Peral A, Karimzadeh H, Pritsch M, Scherer C, Muenchhoff M, Hellmuth JC, von Bergwelt-Baildon M, Olbrich L, Hoelscher M, Wieser A, Kroidl I, Rothenfusser S, Geldmacher C, Krug AB. 
Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination.

  European Journal of Immunology 2023; 53:e2250090.

  JIF2022 4.4
  https://pubmed.ncbi.nlm.nih.gov/36404054/
• Scheck MK, Lehmann L, Zaucha M, Schwarzlmueller P, Huber K, Pritsch M, Barba-Spaeth G, Thorn-Seshold O, Krug AB, Endres S, Rothenfusser S, Thorn-Seshold J.
FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.

  PLOS One 2022; 17:e0262149.
  JIF2021 3.8
  
• Winheim E, Rinke L, Lutz K, Reischer A, Leutbecher A, Wolfram L, Rausch L, Kranich J, Wratil PR, Huber JE, Baumjohann D, Rothenfusser S, Schubert B, Hilgendorff A, Hellmuth JC, Scherer C, Muenchhoff M, von Bergwelt-Baildon M, Stark K, Straub T, Brocker T, Keppler OT, Subklewe M, Krug AB.

  Impaired function and delayed regeneration of dendritic cells in COVID-19.

  PLOS Pathogens 2021; 17:e1009742.

  JIF2020 6.2

  https://pubmed.ncbi.nlm.nih.gov/34614036/
  
• Boehmer D, Formisano S, de Oliveira Mann C, Mueller S, Kluge M, Metzger P, Rohlfs M, Hörth Ch, Kocheise L, Lichtenthaler S, Hopfner KP, Endres S, Rothenfusser S, Friedel C, Duewell P, Schnurr* M, Koenig* L.
  OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.

  Science Immunology 2021; 61, eabe2550.

  JIF2020 30.6

  https://immunology.sciencemag.org/content/6/61/eabe2550
  
• Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmebarek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, Endres S, Kobold S.

  T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

  Nature Biomedical Engineering 2021; 35:2243-2257.

  JIF2020 20.0

  https://www.nature.com/articles/s41551-021-00737-6
• Linder A, Bothe V, Linder N, Schwarzlmüller P, Dahlström F, Bartenhagen Ch, Dugas M, Pandey D, Thorn-Seshold J, Boehmer D, König LM, Kobold S, Schnurr M, Rädler J, Spielmann G, Karimzadeh H, Schmidt A, Endres S, Rothenfusser S.

  Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner.
  Frontiers in Immunology 2021; 12:595390.

  JIF2020 6.4

  http://journal.frontiersin.org/article/10.3389/fimmu.2021.595390/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Immunology&id=595390
  
• Boehmer D, Koehler L, Magg T, Metzger P, Rohlfs M, Ahlfeld J, Rack-Hoch A, Reiter K, Albert M, Endres S, Rothenfusser S, Klein Ch, Koenig L, Hauck F.

  A novel complete autosomal recessive STAT1 LOF variant causes immunodeficiency with hemophagocytic lymphohistiocytosis-like hyperinflammation.

  The Journal of Allergy and Clinical Immunology 2020; 8:3102-3111.

  JIF2019 10.3

  https://pubmed.ncbi.nlm.nih.gov/32603902/
  
• Huber J*, Ahlfeld J*, Scheck M, Zaucha M, Witter K, Lehmann L, Karimzadeh H, Pritsch M, Hölscher M, von Sonnenburg F, Dick A, Barba-Spaeth G, Krug A, Rothenfußer S*, Baumjohann D* .

  Dynamic changes in circulating T follicular helper cell composition predict neutralizing antibody responses after yellow fever vaccination.

  Clinical & Translational Immunology 2020; 9:e1129.

  * equally contributed

  JIF2019 6.5

  https://pubmed.ncbi.nlm.nih.gov/32419947/
  
• Ruzicka M, König L, Formisano S, Boehmer D, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhoefler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger F, Rothenfusser S.
  RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.

  Leukemia 2020; 34:1017-1026.

  JIF2019 9.9
  https://www.ncbi.nlm.nih.gov/pubmed/31740809
  
• Hoffmann F, Schmidt A, Dittmann Chevillotte M, Wisskirchen C, Hellmuth JC, Willms S, Gilmore RH, Glas J, Folwaczny M, Müller T, Berg T, Spengler U, Fitzmaurice K, Kelleher D, Reisch N, Rice CM, Endres S, Rothenfusser S.

  Polymorphisms in MDA-5 link protein function to clearance of hepatitis C virus.

  Hepatology 2015; 61:460-70.

  JIF 10.4
  
• Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.

  Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin-1β production.

  Nature Immunology 2009; 11:63-9.

  JIF 26.2
  
• Schmidt A, Schwerd T, Hellmuth J, Sheng C, Wenzel M, Hoffmann F, Poeck H, Michallet MC, Besch R, Hopfner KP, Endres S, Rothenfusser S.

  5'-triphosphate RNA requires base-paired structures to activate anti-viral signaling via RIG-I.

  Proceedings of the National Academy of Sciences USA 2009; 106:12067-72.

  JIF 9.7
  
• Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya S S, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Häcker G, Neuenhahn M, Busch D H, Rothenfusser S , Prinz M, Hornung V, Endres S, Tüting T, Hartmann G.

  Therapeutic anti-tumor efficacy of 5´-triphosphate-siRNA depends on simultaneous gene-silencing and immuno-stimulatory activity.

  Nature Medicine 2008; 14:1256-63.

  JIF 24.3
  
• Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S, Hartmann G.
  CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

  Blood 2004; 103:2162-9.

  JIF 10.1
  
• Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G.

  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

  Journal of Immunology 2002; 7:34-44.

  JIF 7.3